Freitag, 21. April 2023

Registration and Get Together

Introduction and Opening Remarks

Marc S. Raab, Heidelberg
Hartmut Goldschmidt, Heidelberg
Carsten Müller-Tidow, Heidelberg
Ingo Autenrieth, Heidelberg
Niels Weinhold, Heidelberg

Session I: Evolution & Treatment of SMM

Patrick Hayden, Dublin
Elias Mai, Heidelberg

The evolutionary pathways leading to multiple myeloma

Brian Walker, Indianapolis

Treatment of high-risk smoldering: pros

Maria Victoria Mateos, Salamanca

Treatment of high-risk smoldering: cons

Sagar Lonial, Atlanta


Session II: Minimally Invasive Response Assessment

Chair: Stefan Delorme, Heidelberg

Using PET for response assessment (Update)

Carolina Schinke, Arkansas

Mass spectrometry

Elias Mai, Heidelberg

Using MRI for response assessment (Update)

Jens Hillengass, Buffalo


Coffee Break

Session III: Current Concepts for Newly Diagnosed Myeloma

Hans Salwender, Hamburg
Sandra Sauer, Heidelberg

First-line transplant eligible (Update)

Hartmut Goldschmidt, Heidelberg

CONCEPT trial (Update)

Katja Weisel, Hamburg

MASTER trial (Update)

Ola Landgren, Miami

First-line transplant ineligible

Thierry Facon, Lille


Coffee Break

Key Note Lecture

Novel Agents Beyond Immunotherapy
Shaji Kumar, Rochester

Session IV: Curing Myeloma

Monika Engelhardt, Freiburg
Stefanie Huhn, Heidelberg

Risk-stratified treatment approaches

Martin Kaiser, London

The evolutionary pathways of myeloma cells in deep-responding patients

Leo Rasche, Würzburg

Treatment decisions based on MRD data: pros

Bruno Paiva, Pamplona

Treatment decisions based on MRD data: cons

Martin Kaiser, London


Short Summary and End of Day 1

Marc-Steffen Raab, Heidelberg

Samstag, 22. April 2023

Get Together

Key Note Lecture

What is the Next Bbig Thing in Myeloma Therapy?
Kenneth C. Anderson, Boston

Session I: Myeloma Genomics

Leo Rasche, Würzburg
Niels Weinhold, Heidelberg

Complex structural aberrations and impact on outcome

Gareth Morgan, New York

Mutational signatures

Francesco Maura, Miami

Impact of genomic complexity on the transcriptome of multiple myeloma

Niccolo Bolli, Milano


Coffee Break

Session II: Immunotherapy I

Chair:  Peter Dreger, Heidelberg

CD38 Antibody treatment

Philippe Moreau, Nantes

Current CAR-T cells – Clinical overview

Paula Rodriguez Otero, Pamplona

CAR real world data

Christoph Scheid, Köln

Role of BM microenvironment in MM progression and response to CAR-T therapies in myeloma

Paola Neri, Calgary



Session III: Immunotherapy II

Chair:  Markus Munder, Mainz
Leif Bergsagel, Scottsdale

Novel CAR-T cell constructs

Hermann Einsele, Würzburg

Antibody-drug conjugates

Suzanne Trudel, Toronto

Immune microenvironment stroma cells

Tom Cupedo, Rotterdam

T-cell engagers, a clinical update

Nizar Bahlis, Calgary


Coffee Break

Session IV: Novel Resistance Mechanisms

Christoph Driessen, St. Gallen
Florian Bassermann, München         

PI and IMID Resistance

Martin Kortüm, Würzburg

Combination of SOC and bispecific antibodies: lessons from an IMID-responsive immunocompetent mouse model

Marta Chesi, Scottsdale

Proteomic studies to uncover non-genetic resistance mechanisms in myeloma

Jan Krönke, Berlin

Immunotherapeutic vulnerabilities

Jens Lohr, Boston

Immunological mechanisms and determinants of response to T cell-redirecting therapies

Mirco Friedrich, Cambridge


Summary and Closing of the Workshop

Marc-Steffen Raab, Heidelberg